Cerus (NASDAQ:CERS) Share Price Crosses Above 200 Day Moving Average – What’s Next?

Cerus Corporation (NASDAQ:CERS) shares passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $1.35 and traded as high as $1.53. Cerus shares last traded at $1.51, with a volume of 1,394,861 shares.

Cerus Trading Down 0.7%

The stock has a market capitalization of $289.47 million, a P/E ratio of -15.10 and a beta of 1.70. The company has a current ratio of 2.00, a quick ratio of 1.35 and a debt-to-equity ratio of 1.01. The stock’s fifty day moving average price is $1.32 and its two-hundred day moving average price is $1.35.

Cerus (NASDAQ:CERS) last announced its quarterly earnings data on Tuesday, August 5th. The biotechnology company reported ($0.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.01). The business had revenue of $60.10 million during the quarter, compared to the consensus estimate of $51.80 million. Cerus had a negative return on equity of 33.77% and a negative net margin of 9.81%. Cerus has set its FY 2025 guidance at EPS. Equities research analysts forecast that Cerus Corporation will post -0.08 EPS for the current year.

Institutional Investors Weigh In On Cerus

A number of hedge funds have recently made changes to their positions in CERS. Ameriprise Financial Inc. bought a new stake in shares of Cerus in the 4th quarter worth approximately $40,000. Two Sigma Investments LP raised its holdings in Cerus by 121.6% during the 4th quarter. Two Sigma Investments LP now owns 595,234 shares of the biotechnology company’s stock valued at $917,000 after buying an additional 326,605 shares during the last quarter. Two Sigma Advisers LP raised its holdings in Cerus by 249.5% during the 4th quarter. Two Sigma Advisers LP now owns 254,100 shares of the biotechnology company’s stock valued at $391,000 after buying an additional 181,400 shares during the last quarter. Wealth Enhancement Advisory Services LLC bought a new stake in Cerus during the 4th quarter valued at $25,000. Finally, Rhumbline Advisers raised its holdings in Cerus by 5.5% during the 1st quarter. Rhumbline Advisers now owns 251,907 shares of the biotechnology company’s stock valued at $350,000 after buying an additional 13,112 shares during the last quarter. 78.37% of the stock is currently owned by institutional investors.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.